- Home
- BEAM vs NTB Comparison
BEAM vs NTB Comparison
Compare BEAM & NTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NTB
- Stock Information
- Founded
- BEAM 2017
- NTB 1858
- Country
- BEAM United States
- NTB Bermuda
- Employees
- BEAM N/A
- NTB 1306
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NTB Commercial Banks
- Sector
- BEAM Health Care
- NTB Finance
- Exchange
- BEAM Nasdaq
- NTB Nasdaq
- Market Cap
- BEAM 1.9B
- NTB 1.9B
- IPO Year
- BEAM 2020
- NTB 2016
- Fundamental
- Price
- BEAM $20.62
- NTB $44.15
- Analyst Decision
- BEAM Strong Buy
- NTB Buy
- Analyst Count
- BEAM 11
- NTB 4
- Target Price
- BEAM $48.90
- NTB $49.25
- AVG Volume (30 Days)
- BEAM 2.6M
- NTB 156.5K
- Earning Date
- BEAM 08-05-2025
- NTB 07-28-2025
- Dividend Yield
- BEAM N/A
- NTB 3.98%
- EPS Growth
- BEAM N/A
- NTB 7.68
- EPS
- BEAM N/A
- NTB 4.81
- Revenue
- BEAM $63,578,000.00
- NTB $585,277,000.00
- Revenue This Year
- BEAM N/A
- NTB $3.10
- Revenue Next Year
- BEAM $17.18
- NTB $0.34
- P/E Ratio
- BEAM N/A
- NTB $9.41
- Revenue Growth
- BEAM N/A
- NTB 1.89
- 52 Week Low
- BEAM $13.53
- NTB $33.04
- 52 Week High
- BEAM $35.25
- NTB $46.89
- Technical
- Relative Strength Index (RSI)
- BEAM 55.12
- NTB 43.28
- Support Level
- BEAM $19.40
- NTB $44.07
- Resistance Level
- BEAM $22.76
- NTB $46.44
- Average True Range (ATR)
- BEAM 1.32
- NTB 0.72
- MACD
- BEAM -0.01
- NTB -0.34
- Stochastic Oscillator
- BEAM 38.07
- NTB 2.66
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.